AngioDynamics, Inc. (NASDAQ:ANGO) Shares Acquired by US Bancorp DE

US Bancorp DE lifted its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 1,938.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,705 shares of the medical instruments supplier’s stock after buying an additional 6,376 shares during the period. US Bancorp DE’s holdings in AngioDynamics were worth $61,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Rhumbline Advisers boosted its position in AngioDynamics by 1.7% during the 4th quarter. Rhumbline Advisers now owns 60,479 shares of the medical instruments supplier’s stock worth $554,000 after purchasing an additional 1,021 shares during the period. Quarry LP boosted its position in AngioDynamics by 40.9% during the 3rd quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 2,471 shares during the period. SG Americas Securities LLC boosted its position in AngioDynamics by 21.3% during the 4th quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier’s stock worth $147,000 after purchasing an additional 2,832 shares during the period. Bank of New York Mellon Corp boosted its position in AngioDynamics by 3.2% during the 4th quarter. Bank of New York Mellon Corp now owns 122,676 shares of the medical instruments supplier’s stock worth $1,124,000 after purchasing an additional 3,815 shares during the period. Finally, R Squared Ltd purchased a new stake in AngioDynamics during the 4th quarter worth $49,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Stock Up 6.4 %

ANGO opened at $9.59 on Tuesday. The firm has a market cap of $388.07 million, a price-to-earnings ratio of -1.70 and a beta of 0.56. AngioDynamics, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $13.50. The company’s 50-day moving average price is $10.83 and its 200 day moving average price is $8.65.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.07. The company had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. AngioDynamics’s revenue was down .1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.05) earnings per share. Research analysts anticipate that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, January 10th.

Insider Activity

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the sale, the senior vice president now owns 41,817 shares of the company’s stock, valued at $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.40% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.